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Challenges in Treating Estrogen 
Receptor-Positive Breast Cancer
Shang-Hung Chen and Chun Hei Antonio Cheung
Abstract
Despite hormone therapy is widely used (as both adjuvant and neoadjuvant 
therapy) for the treatment of estrogen receptor-positive (ER+) breast cancer 
and patients receiving hormone therapy often show satisfactory initial response, 
resistance to selective estrogen modulators and aromatase inhibitors is frequently 
found in patients after prolonged treatment. In this chapter, we will discuss the 
molecular mechanisms of action of various hormone therapy agents and the biology 
behind the induction of hormone therapy resistance in ER+ breast cancer cells. 
Recent development of novel agents that can be used to treat ER+ hormone therapy-
resistant breast cancer will also be discussed in this chapter.
Keywords: aromatase inhibitors, breast cancer, estrogen receptor, hormone therapy 
resistance, tamoxifen
1. Introduction
Breast cancer is the most common malignant disease and leading cause of 
cancer-related death for women worldwide. Among all subtypes, estrogen 
receptor-positive (ER+, i.e. expressing estrogen receptors endogenously) breast 
cancer is the most prevalent type, accounting for approximately 75% of all 
patients. In clinical situations, hormone therapy targeting the estrogen (ER)-
estrogen response element (ERE)-regulated cell survival-signaling pathway is 
commonly used for the management of ER+ breast cancer. The goals of applying 
systemic hormone therapy in patients with breast cancers are different in separate 
disease stages and generally hormone therapy can be given to patients with early 
disease prior to surgery (i.e. neoadjuvant therapy) or after surgery (i.e. adjuvant 
treatment), and patients with metastatic disease. There are four major classes of 
hormone therapy agents currently used for the management of ER+ breast cancer 
and they are: selective estrogen receptor modulators (SERMs), aromatase inhibi-
tors (AIs), selective estrogen receptor down-regulators (SERDs), and luteinizing 
hormone-releasing hormone analogs (LHRH analogs). Even though these agents 
are all functioned in interfering with the hormone-dependent cell survival-sig-
naling pathways in breast cancer cells, their mechanisms of action are completely 
different (Figure 1).
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2. Human breast cancer
2.1 Clinical classifications of human breast cancer
Breast cancer is now recognized as a group of diseases with distinct histopatho-
logical and biological characteristics. In the last decade, there is accumulating 
evidence indicating that individualized therapeutic strategies should be applied to 
treat breast cancers with different expression levels of histopathological biomark-
ers which own their unique biological behaviors and treatment responses [1–3]. 
Currently, the most determinant and commonly used molecular markers in clinical 
classifications of breast cancers are ER, progesterone receptor (PR), human epider-
mal growth factor receptor 2 (HER2), and Ki67. The prognoses and most beneficial 
treatments of patients would be best evaluated after comprehensive examinations 
on the expression levels of these molecular markers in tumor cells. In addition to 
conventional risk factors such as tumor size, numbers of lymph node metastasis, 
surgical margin with tumor involvement, and tumor differentiation grade, the 
abovementioned molecular biomarkers have to be included in a modern pathologi-
cal report of breast cancer. Breast cancer classification based on expression levels of 
these four biomarkers are summarized in Table 1.
Immunohistochemical (IHC) staining is the most accepted and widely used 
method to determine the expression levels of these biomarkers (i.e. ER, PR, HER2, 
and Ki67) clinically. Based on St. Gallen Consensus 2009 [4], ER+ and PR+ tumors 
were defined as if 1% or more immuno-reactive cells were identified. Noticeably, 
the definite percentage of breast cancer cells displaying nuclear immuno-reactivity 
for ER and PR must be reported, because the higher numbers of positive cells 
indicates the larger anticipated benefit of hormone treatment.
Figure 1. 
Mechanisms of action of different hormone therapy agents like SERMs, SERDs, AIs, and LHRH analogs. 
Hormones shown in this picture: follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
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2.2 Current treatment options for ER+ breast cancer
2.2.1 Surgery
In general, surgery is the only way to cure most malignancies originated from 
solid organs. After diagnosis, patients with breast cancer in early stage should 
undertake surgery with or without radiotherapy, irrespective to the subtypes of 
breast cancer. There are two major surgical approaches for breast cancers—mastec-
tomy (removal of the whole breast) and lumpectomy (breast-conserving therapy). 
The appealing advantage of lumpectomy enables patients to preserve their breast 
without compromising survival outcome. With the addition of radiotherapy follow-
ing lumpectomy, survival outcomes have been reported to be equivalent to those 
after mastectomy as primary disease control in breast cancers with early stage [5–7].
Besides primary tumor resection, axillary lymph node (ALN) dissection or sen-
tinel lymph node (SLN) biopsy and resection is also essentially performed on breast 
cancer patients to determine possible spread of cancer cells to lymph nodes from the 
original breast tumor. If the SLN examination reveals no evidence of malignant cell 
involvement, any other area of the body without cancer cell metastases would be 
highly postulated. Notably, the effectiveness of the SLN procedure to determine the 
presence of lymph node metastases is demonstrated to be identical to that of ALN 
dissection in various clinical studies.
2.2.2 Selective estrogen receptor modulators (SERMs)
The anti-breast cancer function of SERMs is mainly contributed by the 
competition with estrogen on ER, and modulations on ER-ERE (i.e. a type of gene 
promoter recognized by the activated ER) activity by altering the cooperated 
transcription factors in breast cancer cells (Figure 1) [8]. For both premenopausal 
and postmenopausal patients, the most commonly used SERM with established 
benefit in adjuvant setting is tamoxifen. Interestingly, although tamoxifen 
exhibits anti-estrogenic properties in the breast including the breast cancer cells; 
it exhibits estrogenic properties in bones and endometrial tissues. In ER+ breast 
cancers, the use of tamoxifen after surgery could decrease the risk of recurrence 
as well as death [9–11].
In general, if both chemotherapy and hormone therapy are indicated for patients 
after surgery, the recommended sequence of management is initial chemotherapy 
following with the use of tamoxifen. Traditionally, tamoxifen is given to patients 
with early breast cancer for 5 years after primary surgery. In fact, the NCCN 
guidelines recommend patients to receive at least 5 years of treatment, if tamoxifen 
is considered to be used after surgery. However, results from the recent randomized 
Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) study have supported 10 
years of tamoxifen treatment in the adjuvant setting. The risks of disease recurrence 
Subtype Molecular profile
Luminal A ER+ and/or PR+, HER2+, and low Ki67 (<14%)
Luminal B ER+ and/or PR+, HER2+, and high Ki67 (≥14%)
ER+ and/or PR+ and HER2+ (luminal-HER2 group)
HER2 ER−, PR−, and HER2+
Triple negative ER−, PR−, HER2−
Table 1. 
Molecular profiles of different breast cancer subtypes.
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and death were shown to be decreased in patients completing 10 years of tamoxifen 
treatment, as compared with those for 5 years of treatment, despite the increased 
risks of getting endometrial cancer and pulmonary embolism [9]. Based on these 
findings, adjuvant tamoxifen treatment for 10 years is now considered for patients 
with early breast cancer. The NCCN guidelines also recommend tamoxifen treat-
ment for ER+ metastatic breast cancer patients.
Toremifene is another SERM which has demonstrated its clinical efficacy in 
ER+ breast cancers. Several studies have shown equivalent efficacy of toremifene in 
disease control of metastatic breast cancers, as compared with tamoxifen [12, 13]. 
Therefore, similar to tamoxifen, toremifene is also recommended in NCCN guide-
lines for disease control in patients with ER+ metastatic breast cancers.
2.2.3 Aromatase inhibitors (AIs)
Aromatase is an enzyme that belongs to the family of cytochrome P-450 and it is 
responsible for the conversion of androgens to estrogens in peripheral tissues. Given 
that this peripheral conversion by the aromatase is the main origin of estrogen pro-
duction in postmenopausal women, inhibition of this particular enzyme could lead 
to the significant reduction of estrogens (Figure 1). AIs are now suggested to be 
the standard of care for postmenopausal patients with ER+ breast cancer in NCCN 
guidelines. Current AIs could be grouped into two different subtypes—steroidal 
and non-steroidal AIs. Steroidal AIs, also termed as type I inhibitors, have steroid-
like structure similar to the substrate of aromatase. This similarity confers these AIs 
the ability to interact with the substrate-binding site of aromatase and subsequent 
inactivation of this enzyme. Non-steroidal AIs or type II inhibitors could bind to 
the heme moiety of the aromatase non-covalently, and therefore prevent binding 
of androgens. Unlike type I inhibitor, the inhibition of androgen by this type of AIs 
is reversible by competitive binding of androgens. There are currently one type I 
inhibitor (i.e. exemestane) and two type II inhibitors (i.e. letrozole and anastrozole) 
approved by the US Food and Drug Administration (FDA). They are all indicated 
in both the adjuvant and metastatic setting for postmenopausal patients with ER+ 
breast cancer (Table 2).
Several studies have been carried out to evaluate the effects of different thera-
peutic strategies of AIs in the treatment of postmenopausal patients with early stage 
ER+ breast cancer. Different therapeutic strategies including (1) initial treatment 
with AIs, (2) sequential therapy with AIs after 2–3 years of tamoxifen, and (3) 
extended therapy with AIs after the completion of tamoxifen for 5 years have been 
extensively studied. Two phase III pivotal studies, named ATAC [14] and BIG 1-98 
[15], have demonstrated the clinical efficacy of 5 years of adjuvant AIs (i.e. initial 
treatment with AIs). However, the hazard ratio (HR) for disease-free survival 
(DFS) comparing 5 years of tamoxifen of these studies, ranging from 0.81 to 0.91, 
indicates minimal improvement of the use of AIs to prevent disease recurrence after 
surgery. Several clinical studies, such as ARNO 95 [16], ITA [17], and IES [18] have 
shown the clinical benefit of sequential treatment of AI after 2–3 years of tamoxi-
fen. In patients receiving sequential therapy comparing with 5 years of tamoxifen, 
HR for DFS ranges from 0.57 to 0.76. In extended therapy of AIs beyond 5 years 
of tamoxifen, its clinical efficacy in the reduction of HR for DFS, ranging from 
0.58 to 0.68, has also been reported in randomized studies [19, 20]. According to 
the NCCN guidelines, the abovementioned AIs related strategies (i.e. AIs as initial 
adjuvant therapy for 5 years; 2–3 years of tamoxifen followed by AIs to complete 5 
years of adjuvant therapy; and 5 years of tamoxifen followed by 5 years of AIs) are 
all recommended for postmenopausal breast cancer patients who are required for 
receiving adjuvant hormone therapy.
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In metastatic disease, improved survival outcomes of applying AIs as the 
first-line hormone therapy as compared with using tamoxifen in postmenopausal 
patients have also been revealed in studies conducted by Arimidex Study Group, 
International Letrozole Breast Cancer Group, and the EORTC Breast Group [21–23]. 
Although this advantage is small, AIs are still recommended by NCCN for use in 
treating ER+ metastatic breast cancer in postmenopausal patients.
2.2.4 Selective estrogen receptor degrader (SERD)
Unlike SERMs that function as partial competitive antagonists of ER, SERDs are 
antiestrogens designed to destabilize ER of tumor cells (Figure 1). After binding 
to ERs, SERDs could induce the degradation of these receptors, and thereby lead to 
the inhibition of estrogen associated signaling pathway [24]. Fulvestrant is the only 
SERD approved by FDA for clinical use in the management of ER+ breast cancers. 
Equivalent effect of fulvestrant on tumor response rate and time to progression, 
as compared with AIs, have been reported in postmenopausal patients with pro-
gressive metastatic ER+ breast cancer following prior hormone therapy [25, 26]. 
In NCCN guidelines, fulvestrant is suggested in clinical use of postmenopausal 
metastatic ER+ breast cancers.
2.2.5 Luteinizing hormone-releasing hormone (LHRH) analogs
Ovary is the major organ responsible for estrogen production. Therefore, oopho-
rectomy has been recognized as one of the effective treatments for premenopausal 
patients with metastatic ER+ breast cancers. Besides oophorectomy, medical treat-
ments with LHRH analogs have also been used clinically to ablate ovary function for 
over 30 years [27]. Through desensitizing gonadotropin-releasing hormone (GnRH) 
receptors, LHRH analogs suppress the secretion of gonadotropin, luteinizing hor-
mone (LH) and follicle-stimulating hormone (FSH), resulting in reduced estrogen 
levels in the body (Figure 1). Although a combination of LHRH analogs and SERMs 
Trial Disease 
setting
Study group Control group Significant 
findings
ATAC [14] Adjuvant Anastrozole for 5 years Tamoxifen for 
5 years
HR for DFS: 
0.91
BIG1-98 
[15]
Adjuvant Letrozole for 5 years Tamoxifen for 
5 years
HR for DFS: 
0.81
ARNO95 
[16]
Adjuvant 2 years of tamoxifen +3 years of 
anastrozole
Tamoxifen for 
5 years
HR for DFS: 
0.66
ITA [17] Adjuvant 2–3 years of tamoxifen followed by 
anastrozole to complete total 5 years 
of HT
Tamoxifen for 
5 years
HR for DFS: 
0.56
IES [18] Adjuvant 2–3 years of tamoxifen followed by 
exemestane to complete total 5 years 
of HT
Tamoxifen for 
5 years
HR for DFS: 
0.76
MA17 [19] Adjuvant 4.5–6 years of tamoxifen +5 years of 
letrozole
Tamoxifen for 
5 years
HR for DFS: 
0.58
B33 [20] Adjuvant 5 years of tamoxifen +5 years of 
exemestane
Tamoxifen for 
5 years
HR for DFS: 
0.68
DFS, disease-free survival; HT, hormone therapy; HR, hazard ratio.
Table 2. 
Clinical benefits of using aromatase inhibitors in ER+ breast cancers.
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has been demonstrated to improve survivals significantly as compared to chemo-
therapy alone [28], further studies indicate that in premenopausal patients with ER+ 
early breast cancer, adjuvant treatment with LHRH analogs combined with SERMs 
(tamoxifen) does not carry any clinical benefits [29]. However, the combination of 
LHRH analogs and AIs (i.e. exemestane) as an adjuvant therapy significantly reduces 
the risk of recurrence in premenopausal patients with early disease [30]. In metastatic 
diseases, both the combinations of LHRH analogs and SERMs or AIs have shown the 
benefit of survivals in premenopausal patients [31–33]. In NCCN guidelines, LHRH 
analogs are recommended to use in combination with AIs or SERMs in premeno-
pausal patients with ER+ breast cancer, both in adjuvant or metastatic setting.
2.3. Mechanisms of hormone therapy resistance in ER+ breast cancer
Despite various hormone therapy agents have been developed and proven to be 
effective in treating ER+ early stage breast cancer, intrinsic and acquired resistance 
to hormone therapy are frequently observed in breast cancer patients. In the follow-
ing sections, we will discuss the biology behind the induction of hormone therapy 
resistance in ER+ breast cancer in details.
2.3.1 Dysregulation and conformation alteration of ERα
Under normal physiological conditions, the binding of estrogen to ER will trigger 
ER conformation changes and ER dimerization (e.g. ERαβ heterodimer formations). 
Then, the activated ER dimers will bind onto the estrogen response elements (EREs; 
promotor regions specifically recognized by the activated ER dimers) and drive the 
expression of the ERE-regulated cell survival- and growth-related genes. Decreased 
ERα expression (and aberrant ERα protein conformation) and reduced survival 
dependence on the estrogen-ER signaling pathway are both known to promote 
hormone therapy resistance in ER+ breast cancer. For example, upregulation of the 
zinc-finger-homeodomain transcription factor, zinc-finger E-box binding homeobox 
1 (ZEB1), has been shown to downregulate ERα expression epigenetically through 
formation of a ZEB1/DNA methyltransferase 3B (DNMT3B)/histone deacetylase 1 
(HDAC1) complex on the promoter of ERα and to induce tamoxifen resistance in 
breast cancer cells. High ZEB1 expressions also correlate with ERα promoter hyper-
methylation and reduced ERα expression in breast cancer patients [34].
As described in the above sections, tamoxifen is a SERM that exhibits differential 
effects on ER conformation and ER-signaling pathways. Despite tamoxifen inhibits 
the ER-ERE-related survival-signaling pathways in ER+ breast cancer cells and this 
drug is widely used to treat ER+ breast cancer; tamoxifen is known to increase the 
risk of having endometrial proliferation, endometrial hyperplasia, endometrial 
cancer, and uterine sarcomas in the treated breast cancer patients, possibly through 
activation of the ER-signaling pathways in endometrial cells. Phosphorylation of the 
amino acid residue serine-305 in the hinge region of ERα by protein kinase A (PKA) 
has been demonstrated to change the resulting conformation of ERα upon tamoxifen 
interactions, turning the tamoxifen-bound ERα from an inactive form into an active 
form (i.e. tamoxifen acts as an ER-agonist), leading to the activation of ER-ERE 
signaling pathways in ER+ breast cancer cells (Figure 2) [35].
2.3.2  Dysregulation of cell survival-related signaling pathways and pro-/anti-
apoptotic molecules
It is widely demonstrated that aberrant downregulation of p53, upregulation of 
human epidermal growth factor receptor 2 (HER2/neu), the phosphatidylinositol 
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3-kinase/protein kinase B/mammalian target of rapamycin [PI3K/PKB(Akt)/
mTOR]-signaling pathway, and the extracellular signal-regulated kinases (ERK, also 
called MAPK)-signaling pathway can promote the survival and metastasis of cancer 
cells. In fact, dysregulation of these molecules and signaling pathways has also been 
found in the ER+ hormone therapy resistance breast cancer cells (Figure 2). For 
example, a study by Liang et al. revealed that melanoma cell adhesion molecule 
(MCAM, also called CD146 or MUC18) negatively regulates ERα expression, but 
positively regulates the Akt-signaling pathway, in breast cancer cells. Moreover, 
increased expression of MCAM was found to induce epithelial-mesenchymal transi-
tion (EMT) and tamoxifen resistance via Akt-signaling pathway activation in the 
tamoxifen-resistance breast cancer cells in the same study [36].
Survivin is a well-known anti-apoptotic and pro-tumorigenic molecule. It con-
tains a single baculovirus inhibitor of apoptosis protein repeat (BIR) domain and it 
is believed that survivin binds to caspases through its BIR domain and subsequently 
inhibits the activity of caspases. On the other hand, survivin forms chromosomal 
passenger complex (CPC) with aurora B kinase, borealin, and inner centromere 
protein (INCENP) and successful formation of CPC plays an important role in 
chromosome segregation during mitosis [37, 38]. Survivin protein translation is 
known to be positively regulated by the Akt/mTOR-signaling pathway and dys-
regulation of the Akt/mTOR/survivin pathway is known to be a factor of estrogen-
independence and tamoxifen-resistance causation in the MCF7-derived ER+ breast 
cancer cells [39]. Of note, hyper-phosphorylation of the survivin-binding partner, 
aurora B kinase, has also been demonstrated to be capable of causing fulvestrant 
resistance in ER+ T47D breast cancer cells [40].
Besides dysregulation of the Akt/mTOR-signaling pathway, Yin et al. revealed 
that upregulation of G protein-coupled estrogen receptor (GPER) triggers Erk-
signaling pathway activation, leading to the expression reduction of the BH3-only 
pro-apoptotic molecule, Bim, and induction of tamoxifen resistance in ER+ breast 
cancer [41]. Myeloid cell leukemia-1 (Mcl-1) is a suppressor of Bim and overexpres-
sion of this anti-apoptotic molecule has also been found in MCF7-derived antiestro-
gen-resistant cancer cell lines [42]. Other molecules/pathways that have been found 
to play a role in the induction of hormone therapy resistance in ER+ breast cancer 
are listed in Table 3.
Figure 2. 
Picture showing a few molecules and molecular pathways that are involved in the induction of hormone 
therapy resistance in ER+ breast cancer cells.
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2.3.3 Dysregulation of microRNAs (miRNAs)
MiRNAs are a class of small (20–22 nucleotides) non-coding RNA molecules 
that function in the regulation of gene expression. At the molecular level, 
miRNAs bind onto mRNAs at specific locations (putative binding sites) through 
complementary base-pairing and subsequently inhibit the translation of the 
targeted genes. Given that the expression of various tumor suppressors and 
oncoproteins is known to be regulated by miRNAs; dysregulation of miRNAs 
is believed as one of the causes of tumorigenesis, tumor metastasis, and tumor 
drug resistance in human.
Aberrant expression of different miRNAs has been shown to contribute to the 
induction of hormone therapy resistance through downstream modulations of 
different cell survival or division-related signaling molecules in ER+ breast cancer 
(Figure 2). For example, we found in a previous study that the MCF7-derived, ER+ 
hormone therapy-resistant (i.e. estrogen independent and tamoxifen resistant) 
breast cancer cells, which were generated in our laboratory, exhibits reduced 
expression of miR-125a-5p but increased expression of survivin as compared to the 
parental hormone therapy sensitive MCF7 cells. We also found that miR-125a-5p 
is an expression suppressor of survivin and dysregulation of the HDAC2/5-
miR-125a-5p-survivin pathway in part contributes to the induction of estrogen 
independence and tamoxifen resistance in the same breast cancer cell line [39]. 
The role of miR-125a-5p downregulation in hormone therapy resistance induc-
tion is further supported by clinical data analysis showing that low miR-125a-5p 
expression levels correlate with poor overall survival in tamoxifen-treated ER+ 
breast cancer patients [39]. Induction of tamoxifen resistance has also been shown 
in ER+ breast cancer cells with dysregulation of miR-125a-3p, a molecule which is 
closely related to miR-125a-5p. A study by Zheng et al. revealed that miR-125a-3p 
is an inhibitor of cyclin-dependent kinase 3 (cdk3), which is an ER transcriptional 
activity enhancer, in ER+ breast cancer cells. In addition, reduced expression of 
miR-125a-3p and increased expression of cdk3 was found in the ER+ tamoxifen-
resistant breast cancer cells and ectopic overexpression of miR-125a-3p was shown 
to decrease the expression of cdk3 and restore the sensitivity to tamoxifen in the 
same cell line in vitro [47].
Metabolic reprogramming is believed as one of the mechanisms that can pro-
mote drug resistance in cancer cells. Interestingly, aberrant upregulation of miR-155 
has been found to drive metabolic reprogramming via miR-143 downregulation and 
hexokinase-2 (HK2; a glycolysis-priming enzyme and a known target of miR-143) 
upregulation, promoting the survival of ER+ breast cancer cells under estrogen-
deprived conditions (mimics aromatase inhibitors treatment) [48]. Other miRNAs 
that have been found to play a role in the induction of hormone therapy resistance 
in ER+ breast cancer are listed in Table 4.
Name of the molecule or signaling pathway Reference
MTDH-PTEN-Akt Xu et al. [43]
Plk1-Cdc25c Jeong et al. [44]
RUNX2-ER-SOX9 Jeselsohn et al. [45]
Rac1-PAK1 Gonzalez et al. [46]
Table 3. 
List of molecules/pathways known to contribute to the induction of hormone therapy resistance in ER+ breast 
cancer during dysregulated situations.
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2.3.4 Tumor microenvironment
Emerging evidences suggest that altered tumor microenvironment promotes drug 
resistance induction and malignant progression of cancer. As a tumor grows, tumor 
cells located at a distal distance from blood vessels will experience a hypoxic environ-
ment and eventually some of the severe hypoxia-experienced tumor cell will undergo 
necrosis or apoptosis. However, tumor cells are known to be capable of carrying a 
series of cellular and molecular changes in order to maintain their survival and also 
to promote tumor progression under hypoxic conditions. For example, it has been 
reported that hypoxia induces downregulation of ERα, upregulation of hypoxia-
inducible factor 1α (HIF-1α; a transcription factor known promote the expression of 
various cell survival-related proteins) and vascular endothelial growth factor (VEGF; 
a growth factor known to promote angiogenesis) expressions, and promotes the 
development of estrogen independence in ER+ breast cancer cells in vitro.
Cancer-associated fibroblasts (CAFs) have been implicated in the development 
of hormone therapy resistance in ER+ breast cancer [54, 55]. It has been demon-
strated that CD146-negative CAFs suppress ER expression in ER+ breast cancer 
cells, decrease tumor cell sensitivity to estrogen, and increase tumor cell resistance 
to tamoxifen therapy [55]. As mentioned in the previous section, GPER upregula-
tion triggers Erk-signaling pathway activation and Bim downregulation in ER+ 
breast cancer cells. A study by Yuan et al. demonstrated that GPER also positively 
regulates the expression of an adhesion molecule, β1-integrin, and the downstream 
molecules of β1-integrin, FAK, and Scr, in the MCF7-derived tamoxifen-resistant 
breast cancer cells. Importantly, they further showed that the product of CAFs, 
fibronectin, interacts with β1-integrin and promotes epithelial-mesenchymal 
transition (EMT) in breast cancer cells [56].
3. Combating ER+ hormone therapy-resistant breast cancer
As described in the above sections, overexpression of survivin, aurora B kinase, 
and Mcl-1 has been found in different ER+ hormone therapy-resistant breast 
cancer models. In fact, survivin, aurora B kinase, and Mcl-1 are all known to play 
important roles in maintaining cancer cells survival and metastasis in ER+ breast 
cancer, HER2+ breast cancer, and the triple-negative breast cancer. Therefore, it is 
not surprising to see that the effectiveness of a group of survivin, aurora B kinase, 
and Mcl-1 inhibitors in targeting ER+ hormone therapy-resistant breast cancer has 
Name of 
microRNA
Demonstrated effects in ER+ breast cancer cells Reference
miR-27b Tamoxifen resistant Li et al. [49]
miR-214 Fulvestrant resistant
Tamoxifen resistant
Yu et al. [50]
miR-320a Tamoxifen resistant Lü et al. [51]
miR-375 Tamoxifen resistant Ward et al. [52]
miR-378a-3p Estrogen independent (aromatase inhibitors-resistant)
Tamoxifen resistant
Ikeda et al. [53]
Table 4. 
List of miRNAs known to contribute to the induction of hormone therapy resistance in ER+ breast cancer 
during dysregulated situations.
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been investigated extensively in different pre-clinical studies. For example, a small 
molecule inhibitor of survivin, YM155 (sepantronium bromide), has previously 
been demonstrated to exhibit similar potency in MCF7 and MCF7-derived ER+ 
tamoxifen-resistant breast cancer cells regardless to the expression of p53 [57]. 
Interestingly, the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitor and the anti-cholesteremic agent, lovastatin (mevacor), has been shown 
to decrease survivin expression and increase the therapeutic effect of tamoxifen 
in tamoxifen-resistant breast cancer cells [58]. Targeting aurora B kinase by small 
molecule inhibitor, AZD1152 (barasertib), has also been shown to potentiate the 
effects of fulvestrant in patient-derived estrogen-independent ER+ breast cancer 
cells [40]. Moreover, a dual aurora kinase and cyclin-dependent kinase inhibitor, 
JNJ-7706621, and a deubiquitinase inhibitor (i.e. capable of destabilizing Mcl-1), 
WP1130, have both been demonstrated to be functional in promoting the death of 
tamoxifen-resistant breast cancer cells [42].
SAHA (vorinostat) is an epigenetic modulator [histone deacetylase inhibitor 
(HDACi)] that was approved by the US FDA for the treatment of cutaneous T cell 
lymphoma on 2006. A study by Lee et al. revealed that SAHA preferentially inhibits 
HDAC3, HDAC6 and their downstream targets, survivin and XIAP, in MCF7 and 
MDA-MB-231 breast cancer cells in vitro [59]. Notably, a phase II clinical study 
revealed that the combination of SAHA and tamoxifen exhibited encouraging 
activity in reversing hormone resistance in patients with hormone therapy-resistant 
breast cancer [60]. Besides epigenetic modulators, the possibility of using Akt/
mTOR-signaling pathway inhibitors in treating ER+ hormone therapy-resistant 
breast cancer has also been evaluated in different pre-clinical and clinical studies. 
For example, the orally bioavailable ATP-competitive mTOR inhibitor, AZD8055, 
was found to be more potent against the proliferation of the MCF7-derived tamox-
ifen-resistant breast cancer cells than that of parent cells [61]. In addition, co-treat-
ment with the mTOR inhibitor, rapamycin (sirolimus), was shown to be capable of 
restoring tamoxifen sensitivity in ER+ tamoxifen-resistant breast cancer cells [62]. 
AZD5363 is a pan-Akt kinase catalytic inhibitor and it is currently in phase I clinical 
trials for various cancers. A study by Ribas et al. demonstrated that AZD5363 was 
capable of inhibiting the growth of the ER+ estrogen-independent MCF7-LTED, 
T47D-LTED, and ZR75-LTED breast cancer cells at the low-to-middle nanomolar 
range in vitro. In addition, combination of AZD5363 with fulvestrant was shown 
to exhibit synergistic anticancer effects in a patient-derived luminal breast cancer 
xenograft HBCx22OvaR model [63]. The pan-class I PI3K inhibitor, BKM120 
(buparlisib), is currently in a phase III study in combination with fulvestrant in 
postmenopausal patients with ER+, HER2− breast cancer refractory to non-steroidal 
aromatase inhibitors (ClinicalTrials.gov Identifier: NCT01610284).
4. Conclusion
Since hormone therapy is the mainstay of treatment in early ER+ breast cancer, 
hormone therapy resistance represents the major challenge in the management of 
this disease. Dysregulation of various cell survival-signaling pathways (such as Akt/
mTOR and PI3K) and molecules (like HDACs, survivin, and miR-125a-5p) in breast 
cancer cells and CAFs in tumor microenvironment is now known to contribute to 
the induction of hormone therapy resistance in ER+ breast cancer. Therefore, co-
treatments of mTOR inhibitors like rapamycin or HDACi like SAHA with SERMs/
Als may give better therapeutic (i.e. clinical) outcomes in patients with advanced/
hormone therapy-resistant ER+ breast cancer in the future. Furthermore, even 
though the effectiveness of hormone therapy in patients with ER+ breast cancer 
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can be predicted based on their breast cancer subtypes classified according to the 
results of the pre-treatment pathological examinations using IHC and PAM50 
(Prosigna®); however, there is still room for the improvement of the current breast 
cancer pathological classification system as intrinsic resistance to hormone therapy 
is frequently found in patients with breast cancer predicted to be hormone therapy 
sensitive. A better breast cancer pathological classification system is needed for the 
development of personalized breast cancer treatments in the future.
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